Can anti-TNFα Antibodies Affect SARS-CoV-2 Disease Outcomes?

2021 ◽  
Author(s):  
Mohammad Reza Khazdair
Keyword(s):  
Disease Outcomes

Astrocyte polarization in perinatal white matter injury and its contribution to disease outcomes

2019 ◽  
Author(s):  
A Brosius Lutz ◽  
P Renz ◽  
M Spinelli ◽  
V Haesler ◽  
S Liddelow ◽  
...  
Keyword(s):  
White Matter ◽  
White Matter Injury ◽  
Disease Outcomes

scholarly journals The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes

2021 ◽  
Author(s):  
Valentin Sencio ◽  
Marina Gomes Machado ◽  
François Trottein
Keyword(s):  
Gut Microbiota ◽  
Bacterial Infections ◽  
Respiratory Infections ◽  
Critical Role ◽  
Good Health ◽  
Disease Outcomes ◽  
And Function ◽  
Viral Respiratory Infections ◽  
The Impact ◽  
Viral Respiratory

AbstractBacteria that colonize the human gastrointestinal tract are essential for good health. The gut microbiota has a critical role in pulmonary immunity and host’s defense against viral respiratory infections. The gut microbiota’s composition and function can be profoundly affected in many disease settings, including acute infections, and these changes can aggravate the severity of the disease. Here, we discuss mechanisms by which the gut microbiota arms the lung to control viral respiratory infections. We summarize the impact of viral respiratory infections on the gut microbiota and discuss the potential mechanisms leading to alterations of gut microbiota’s composition and functions. We also discuss the effects of gut microbial imbalance on disease outcomes, including gastrointestinal disorders and secondary bacterial infections. Lastly, we discuss the potential role of the lung–gut axis in coronavirus disease 2019.

scholarly journals Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

2021 ◽  
Vol 11 (8) ◽  
Author(s):  
Andrew Staron ◽  
Luke Zheng ◽  
Gheorghe Doros ◽  
Lawreen H. Connors ◽  
Lisa M. Mendelson ◽  
...  
Keyword(s):  
Standards Of Care ◽  
Al Amyloidosis ◽  
Unexpected Death ◽  
Related Factors ◽  
Term Survival ◽  
Natural History Study ◽  
Boston University ◽  
Disease Outcomes ◽  
Patient Subgroups ◽  
Over Time

AbstractThe recent decades have ushered in considerable advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis. As disease outcomes improve, AL amyloidosis-unrelated factors may impact mortality. In this study, we evaluated survival trends and primary causes of death among 2337 individuals with AL amyloidosis referred to the Boston University Amyloidosis Center. Outcomes were analyzed according to date of diagnosis: 1980-1989 (era 1), 1990-1999 (era 2), 2000-2009 (era 3), and 2010-2019 (era 4). Overall survival increased steadily with median values of 1.4, 2.6, 3.3, and 4.6 years for eras 1–4, respectively (P < 0.001). Six-month mortality decreased over time from 23% to 13%. Wide gaps in survival persisted amid patient subgroups; those with age at diagnosis ≥70 years had marginal improvements over time. Most deaths were attributable to disease-related factors, with cardiac failure (32%) and sudden unexpected death (23%) being the leading causes. AL amyloidosis-unrelated mortality increased across eras (from 3% to 16% of deaths) and with longer-term survival (29% of deaths occurring >10 years after diagnosis). Under changing standards of care, survival improved and early mortality declined over the last 40 years. These findings support a more optimistic outlook for patients with AL amyloidosis.

Sign in / Sign up

Export Citation Format

Share Document